Lexaria Bioscience Corp. (NASDAQ: LEXX) Grows Global Patent Portfolio To 41 Maintains Focus On GLP-1 Clinical Studies For 2024
Date
8/30/2024 4:22:06 AM
(MENAFN- Investor Brand Network)
Lexaria, a global innovator in drug delivery platforms, has added three new patents to its portfolio, bringing the total to 41
Two patents were awarded in the U.S., while the third was awarded in Japan, expiring in 2042 and 2041, respectively, if not extended
Lexaria's management plans to maintain focus on GLP-1 studies for 2024
Lexaria Bioscience (NASDAQ: LEXX) , a global innovator in drug delivery platforms, in the month of April 2024, added three new patents to its portfolio. This brings the total number of awarded patents globally to 41, a testament to the versatility of its patented DehydraTECH(TM) technology and its overall viability in the potential treatment of various ailments including, but not limited to, diabetes, weight loss and hypertension.
Two newly granted patents were awarded in the U.S. They fall under Lexaria's patent family #24: Compositions and Methods for Treating Epilepsy. These two patents complement earlier research that discovered DehydraTECH-CBD was capable of mitigating epileptic seizures in animals, and was also...
Read More>>
NOTE TO INVESTORS:
The latest news and updates relating to LEXX are available in the company's newsroom at
About CBDWire
CBDWire
(“CBDW”) is a specialized communications platform with a focus on CBD related news and updates in the cannabidiol (“CBD”) sector. It is one of 60+ brands within
the
Dynamic Brand Portfolio
@
IBN
that delivers :
(1) access to a vast network of wire solutions via
InvestorWire
to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ;
(2) article and
editorial syndication to 5,000+ outlets ;
(3) enhanced
press release enhancement
to ensure maximum impact ;
(4)
social media distribution
via IBN to millions of social media followers ;
and (5) a full array of tailored
corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, CBDW brings its clients unparalleled recognition and brand awareness.
CBDW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from CBDWire, text“CBDWire” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published:
/Disclaimer
CBDWire
Denver, CO
303.498.7722 Office
...
CBDWire is powered by
IBN
MENAFN30082024000224011066ID1108618575
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.